LEIDEN, NETHERLANDS -- (MARKET WIRE) -- January 11, 2007 -- Sittard/Leiden, The Netherlands, 11 January 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics today announced that they have signed a PER.C6® research license agreement with the Taiwan-based AbGenomics Corporation. AbGenomics Corporation intends to use the PER.C6® cell line for its research, development and early clinical studies of monoclonal antibodies.
